Drugs that contain Loteprednol Etabonate
1. Alrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Market Authorisation Date: 09 March, 1998
Treatment: Alrex ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
Dosage: SUSPENSION/DROPS;OPHTHALMIC
ALREX family patents
2. Eysuvis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11219596 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11596599 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10945948 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10940108 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10857096 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10993908 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646436 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 26, 2023 |
Market Authorisation Date: 26 October, 2020
Treatment: A method for delivering a composition to a mucus membrane; A method for treating dry eye in a patient; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
3. Inveltys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646437 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11219597 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10864219 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 22, 2021 |
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for treating inflammation and/or other disorders in an eye ...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
4. Lotemax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4996335 (Pediatric) | BAUSCH AND LOMB | Soft steroids having anti-inflammatory activity |
Sep, 2012
(11 years ago) | |
| US5540930 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
| US5747061 | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
|
US5747061 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
|
US5540930 (Pediatric) | BAUSCH AND LOMB | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) | |
Market Authorisation Date: 09 March, 1998
Treatment: Lotemax ophthalmic suspension is indicated for the treatment of steroid responsive conditions of the palpebral bulbar conjunctiva, cornea and anterior segment of the globe.
Dosage: SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX family patents
5. Lotemax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5540930 | PHARMOS | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(10 years ago) | |
Market Authorisation Date: 09 March, 1998
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX family patents
6. Lotemax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5800807 | BAUSCH AND LOMB INC | Ophthalmic compositions including glycerin and propylene glycol |
Jan, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-229) | Jul 20, 2021 |
| New Dosage Form(NDF) | Sep 28, 2015 |
Market Authorisation Date: 28 September, 2012
Treatment: NA
Dosage: GEL;OPHTHALMIC
LOTEMAX family patents
7. Lotemax Sm patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534395 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Jan, 2036
(11 years from now) | |
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Feb 22, 2022 |
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
LOTEMAX SM family patents